PMV Pharmaceuticals PMVP
PMV's Phase I readout on May 26 will disappoint: PC14586 is too weak, too toxic, and too short-lived to win FDA approval, leaving only $295M of cash behind a $628M market cap.
Thesis
Wolfpack Research argues that PMV Pharmaceuticals' lead oncology candidate PC14586, an oral small molecule targeting the p53 Y220C mutation, will fail when Phase I data drop on May 26, 2022. Preclinical mouse studies required doses up to 100 mg/kg (≈570 mg/day in humans) for tumor regression while competitor Kymera's KT-253 shows IC50 in the picomolar range — roughly 100x more potent. The drug also has a 7.5-hour half-life that bounces back to baseline within 24 hours, a narrow therapeutic window, and questionable selectivity beyond Y220C. A key mechanism gel in PMV's investor deck appears photoshopped, and management has stopped advancing follow-on R273H/R282W programs while pivoting to a new WIP1 target. Wolfpack draws an explicit parallel to Aprea Therapeutics (APRE), whose similar p53 reactivator eprenetapopt failed in late 2020 and the stock dropped 77%. With $628M market cap and only $295M cash, downside is steep.
SCQA
PMV Pharmaceuticals is a single-asset oncology biotech whose entire $628M valuation rests on PC14586, an oral small molecule designed to reactivate the p53 Y220C mutation found in roughly 1% of cancers.
Preclinical data show low potency (IC50 0.19-8.6 µM vs Kymera's picomolar), a 7.5-hour half-life, narrow therapeutic window, possibly photoshopped mechanism gels, and management is already pivoting to WIP1 — signs the Phase I readout will disappoint.
Short PMVP into the May 26, 2022 Phase I abstract release; assume the lead and similar R273H/R282W programs are worthless and assign no value to the speculative WIP1 pivot.
Downside roughly mirrors Aprea's 77% post-failure crash: stock at $13.77 against ~$295M cash implies the equity is worth a fraction of the current $628M market cap.
The three reasons
- 1
Preclinical gel image appears photoshopped, suggesting cherry-picked mechanism data
- 2
PC14586 needs ~570 mg/day in humans — Kymera's KT-253 is ~100x more potent
- 3
Drug has 7.5-hour half-life and narrow therapeutic window, unlikely to clear FDA
Primary demands
- Short PMVP ahead of Phase I readout
- Reassess valuation against $295M net cash floor
KPIs cited
Pattern membership
Precedents cited
- Aprea Therapeutics / eprenetapopt (APR-246) failure (Dec 2020, -77%)
- Kymera Therapeutics KT-253 (MDM2 degrader) as potency benchmark
Composition what's on the 18 slides
Slide gallery ·
Notes
Short report by Wolfpack Research dated just before the PMV Phase I readout (May 26, 2022). Format is a Word-style memo with embedded screenshots from PMV's own investor deck and 10-K, annotated with Wolfpack's commentary (red circles, blue boxes, 'Same protein?' callouts). No named human author — credited only to the firm. Strong rhetorical pattern: pull management's own slide, point out a flaw, contrast with peer (Kymera, Aprea). Photoshop allegation on the gel image (p4) is the standout visual claim. Aprea precedent on p15 acts as the analogue/scare chart. Disclaimer makes clear WPR holds a short position. Catalyst-driven short — thesis is timed to a specific binary event 7 days out.